Clinical trial design could benefit from new estimates of how slowly amyloid accumulates and how best to detect it at various disease stages.
BACE inhibitors are shaping up; pyroglutamate Aβ antibody clears plaques without ARIA, but immune reaction raises a flag.
Researchers at AAIC discussed technical limitations of current tracers and ways to improve the signal. A new ligand debuted that may be more specific for tangles.
Researchers at AAIC presented congruent data on the place tau tangles take in AD progression, and their close correlation with cognitive decline.
As data pours in, DIAN leaders strive to share and publish it without accidentally disclosing mutation status. The more is learned about preclinical AD, the harder this may get.
Armed with what they consider comprehensive data sets from the DIAN initiative, researchers are beginning a quest to settle an old question that may become key to drug approvals for late-onset AD.
At AAIC, updated imaging data in autosomal-dominant AD shows that longitudinal MRI in large numbers of people confirms atrophy patterns. Tau PET is more variable in DIAN participants than in the Colombian families.
Serial measurements on hundreds of people in the Dominantly Inherited Alzheimer’s Network put proposed staging diagrams on an empirical footing. CSF markers sTREM2 and VILIP-1 track tau.
At AAIC, 28 scientific presentations and five attendant meetings of the Dominantly Inherited Alzheimer’s Network showed how data is rolling in while the platform expands to more countries and a second therapeutic trial.
Dementia incidence in intervention group was no different from control, though targeting hypertension may protect, researchers say.
Clinical trial centers are preparing to position themselves as standing networks, with standardized paperwork, clinical rater systems, and a central IRB, for trials anticipated to start late next year.
Alarmed by crushing screen failure rates of the first prodromal Alzheimer’s trials, EPAD and GAP are chasing new ways to reach people who don’t know they really should be in a secondary prevention trial.
This past year, the Global Alzheimer’s Platform and the European Prevention of Alzheimer’s Dementia have moved quickly, and jointly, to pave the way toward more, faster, cheaper trials. Will they be better, too?
At AAIC, researchers suggested splitting out the markers in a new staging scheme. Called ATN, it aims to clarify underlying causes of atypical dementias and suspected non-Alzheimer’s pathology (SNAP).
Claims of a positive effect in a small subgroup of patients are statistically meaningless, experts say.